Deferoxamine induces hypotension in experimental gram-negative septicemia

Shock. 1994 Mar;1(3):221-7. doi: 10.1097/00024382-199403000-00011.

Abstract

Multiple organ system failure may result from tissue damage caused by activated neutrophils or endotoxin. A significant part of this tissue damage is due to peroxidation induced by oxygen-free radicals and requires iron as a co-factor. Iron chelation has been shown to prevent tissue damage in some models. This experiment was carried out to determine whether iron chelation with deferoxamine (DFO) would prevent lung damage in a swine model of Gram-negative septicemia. Fifteen animals were randomized to control, Pseudomonas aeruginosa infusion at a rate of 2 x 10(7) colony forming units/20 kg/min (septic group), or Pseudomonas infusion combined with DFO pretreatment at a dose of 80 mg/kg/h (septic-treated group). Three of six septic-treated animals became severely hypotensive and died during the course of the experiment as opposed to none of six septic animals. Surviving septic-treated animals were significantly hypotensive (60 +/- 24 mmHg mean arterial pressure) compared to septic (122 +/- 9 mmHg) and control (109 +/- 8 mmHg) animals. DFO did not improve respiratory function (e.g., pO2) or morphology in septic animals. We conclude that iron-chelation therapy with DFO at the above dosage results in a significant deterioration in cardiovascular function in septic swine. Lung damage was not prevented.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Deferoxamine / pharmacokinetics
  • Deferoxamine / pharmacology*
  • Disease Models, Animal
  • Gram-Negative Bacterial Infections / complications
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / mortality
  • Hemodynamics
  • Hypotension / chemically induced*
  • Hypotension / complications
  • Hypotension / mortality
  • Lung / physiopathology
  • Pseudomonas aeruginosa
  • Respiration Disorders / physiopathology
  • Survival Rate
  • Swine

Substances

  • Deferoxamine